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CHAPTER ONE

INTRODUCTION

1.1

The Warburg Effect
Uncontrolled division of cancer cells requires a reliable energy source to assure

cell survival. The German physiologist, Otto Warburg noticed that cancer cells utilize a
higher amount of glucose comparing to noncancerous cells (Vander Heiden, Cantley &
Thompson, 2009). Not only do cancer cells consume more glucose, but the metabolic
pathway they employ to break down glucose also differs from the pathway used by
normal cells. Most noncancerous cells, except for red blood cells and white skeletal
muscles, tend to metabolize glucose using the fermentation pathway only in the absence
of oxygen. Yet in cancerous tissue, cells rely on the pyruvate reduction to lactate for
energy production even in the presence of oxygen (Halestrap & Price, 1999). This
phenomenon was first described by Otto Warburg, and is referred to as “the Warburg
effect” or aerobic glycolysis (Vander Heiden et al., 2009). While most normal cells
predominantly break down glucose through the Krebs cycle, cancer cells rely heavily on
glycolysis for energy production while still utilizing the TCA cycle, and produce lactate
as a byproduct, shown in Figure 1.1 (Kim, Dang, 2006; Vander Heiden et al., 2009). The
conditions under which the cell chooses the fermentation pathway differ in tumor cells
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Figure 1.1. A schematic representation of anaerobic glycolysis and lactate export
through MCT1 and MCT4. Cancer cells rely heavily on glycolysis for energy
production in the presence of oxygen and produce lactate as a byproduct. Pyruvate
generated from breakdown of glucose is reduced to lactate in a reaction catalyzed by
lactate dehydrogenase. A molecule of lactate and a proton can then be simultaneously
exported out of the cell by one of the monocarboxylate transporters expressed on the cell
membrane (Pinheiro et al., 2012).
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and normal cells (Seyfried, & Shelton, 2010). Anaerobic glycolysis happens when the
cell is deprived of oxygen, while aerobic glycolysis takes place due to the damaged
respiration and in the presence of oxygen (Seyfried et al., 2010). Warburg argued that the
increase in fermentation was the outcome of irreversible respiration damage in cancer
cells, and therefore was simply a way to compensate for the loss of energy normally
generated by oxidative phosphorylation. His theory was proven wrong in 1951 due to
some cancer cells having healthy respiration (Weinhouse, Millington, & Wenner, 1951)

1.2

Aerobic glycolysis in cancer cells and its advantages

During glycolysis, which takes place in the cytosol, glucose is broken down to pyruvate,
a three-carbon molecule (Senyilmas, & Teleman, 2015). The conversion of glucose into
pyruvate results in net total of two ATP molecules, and a reduction of two NAD+
molecules. The electron acceptor NAD+ is required for further glycolysis, hence pyruvate
has to be further metabolized to regenerate the NAD+ (Senyilmas et al., 2015). In animal
cells in the presence of oxygen, pyruvate is further oxidized by pyruvate dehydrogenase
(PDH) to acetyl-CoA, which then participates in tricarboxylic acid (TCA) cycle (Zuo et
al., 2015). As a result of this pathway, 30-36 molecules of ATP are generated as an
energy source for the cell. However, if the cell does not possess an adequate amount of
oxygen for oxidative phosphorylation to take place, a molecule of pyruvate can be
metabolized to lactate.
It was proposed that glycolysis provides a growth advantage for cancer tissue,
because it generates a carbon intermediate molecule which can be further recycled to
generate glucose for utilization in oxidative phosphorylation in neighboring cells of
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heterogeneous tumors (Vander Heiden et al., 2009; Sonveaux et al., 2008). At the same
time the conversion of pyruvate into lactate could be used by cancer cells in an attempt to
prevent acidosis by consumption of protons in the course of lactate fermentation
catalyzed by lactate dehydrogenase, depicted in Figure 1.3. Surprisingly, the term “lactic
acidosis” is a common misconception of the origin of the protons (Robergs, 2004). In
actuality, ATP hydrolysis during glycolitic reaction is the main source of cytosolic proton
production and accumulation (Robergs, 2004). The Figures 1.2 shows the net inputs and
outputs of glycolysis. The molecule of glucose is metabolized to 2 molecules of pyruvate
with the net generation of two molecules of ATP, two molecules of NADH and a gain of
two free cytosolic protons. Additionally, in figure 1.4 the steps of proton generation in
glycolysis are shown in greater detail, with indicated substrates, and enzymes involved,
as well as the products of each reaction. First, an addition of a phosphate group to a
glucose molecule, which creates glucose-6-phosphate, and a transition of fructose into
fructose 1,6-bisphosphate, catalyzed by a hexokinase and a phosphofructokinase,
respectively, both create a free proton from the hydroxyl groups on the six carbon sugar
molecules, as they are phosphorylated. Steps seven and steps ten are performed in
duplicate as they occur on the three-carbon chain molecule. In step seven, a free proton is
generated in the oxidation of glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate. In
step ten, the final step in glycolysis, phosphoenolpyruvate is reduced to pyruvate,
utilizing a free proton. In terms of only protons, the net results of glycolysis is the
generation of two free cytosolic protons. With that being said, the hydrolysis of ATP
molecules in glycolysis leads to a release of protons, and, if the rate of glycolysis is high,
such as during an increased exercise intensity, the accumulation of protons may
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eventually lead to acidosis (Robergs, Ghiasvand, & Parker, 2004). Generally, multiple
buffering systems of the cell work efficiently to prevent the accumulation of the protons.
Yet, when the prolonged rate of proton production exceeds the rate of proton removal, the
accumulation of protons inevitably leads to a metabolic acidosis, Figure 1.5 (Robergs et
al., 2004). To avoid a decrease in intracellular pH, lactate molecules and the protons need
to be quickly and efficiently exported out of the cell (Halestrap et al., 1999). The function
of exporting a lactate and the protons out of the cell is performed by proton-linked
monocarboxylate transporters. Despite the belief that pyruvate reduction to lactate
(fermentation) is the main cause of acidosis, lactate production actually assists in
preventing a pH drop inside the cell. The products of pyruvate reduction, a lactate
molecule and a hydrogen atom are simultaneously exported out of the cell by the means
of a monocarboxylate transporter. Hence, lactate production relieves the proton
accumulation by assisting in a transport of a proton out of the cell. One of the possible
advantages of an anaerobic glycolysis is the ability of tumor cells to adapt to the acidic
environments caused an increased glycolysis level, while creating a toxic extracellular
environment to the cells surrounding the tumor (Gatenby & Gillies, 2008). Additionally,
the acidic extracellular microenvironment created by tumor cells allows for an increased
motility in invasive cancers (Gatenby et al., 2008).
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Figure 1.2. The net result of glycolysis. The cartoon figure shows the net inputs and
outputs of glycolysis. One molecule of glucose is metabolized to 2 molecules of pyruvate
with the net production of two molecules of ATP, two molecules of NADH and a gain of
two free cytosolic protons. Modified from Figure 13.4, Essential Cell Biology, 4thedition
( Garland Science 2014).
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Figure 1.3. The net inputs and outputs of fermentation. The cartoon figure shows the
net inputs and outputs of fermentation. Under anaerobic conditions pyruvate is oxidized
by lactate dehydrogenase to lactate, to recycle the NAD+ to allow continuation of
glycolysis. This reaction involves a double reduction, with a free proton forming a
hydroxyl group and the proton being donated to the carbon atom by NADH. After
fermentation the net output of glycolysis and fermentation is two molecules of lactate, 2
molecules of ATP and no net gain or loss in cytoplasmic free protons. Modified from
Figure 13.6a, Essential Cell Biology, 4th edition ( Garland Science 2014).
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Figure 1.4. A detailed look at the proton producing and proton utilizing steps in
glycolysis. The cartoon figure shows the proton using and generating steps in glycolysis.
Step one and step three of glycolysis both generate a free proton from the hydroxyl
groups on the six carbon sugar molecules, as they are phosphorylated. Steps seven and
steps ten are performed in duplicate as they occur on the three carbon chain molecule. In
step seven, a free proton is generated in the oxidation of glyceraldehyde 3-phosphate to
1,3-bisphosphoglycerate. In step ten, the final step in glycolysis, phosphoenolpyruvate is
reduced to pyruvate, utilizing a free proton. In terms of only protons, the net results of
glycolysis is the generation of two free cytosolic protons. This figure was modified from
Figure 13.1, Essential Cell Biology, 4th edition ( Garland Science 2014).
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Figure 1.5. The source of the free protons and cytosolic acidification generated
during anaerobic metabolism. In the case of Warburg metabolism, metabolic acidosis
results when the rate of ATP hydrolysis, exceeds the rate at which ATP is produced by
the mitochondria. Hence, the biochemical mechanism of proton accumulation is not
lactate production (which in combination with glycolysis, shows no gain or loss in proton
balance), but ATP hydrolysis. The balance of protons will be the sum of all reactions that
release protons, all reactions that consume protons, cellular buffering capacity, and most
importantly, rate of proton export out of the cell. However, as the rate of ATP hydrolysis
exceeds all other reactions, the rate of proton release eventually exceeds metabolic proton
buffering and saturates the proton export mechanisms, protons will accumulate inside the
cell and cytosolic acidification results. This figure was modified from Robergs et al.,
2004.
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1.3

The importance of the Warburg effect in K562, MCF7 and MDA-MB-231

cancer cell lines
Increased tyrosine kinase signaling regulates the Warburg effect in cancer cell
lines and this could underlie the mechanism of higher glucose utilization, lactate
production and increased and cell proliferation (Hitosugi et al., 2009). In K562 cells,
activation of the glycolytic enzyme pyruvate kinase isozyme M2, by a tyrosine kinase
diverts the pyruvate into the fermentation pathway and provides a metabolic advantage to
tumor cells promoting tumor growth (Hitosugi et al., 2009). A common cancer
chemotherapeutic strategy is to decrease this altered energy production, for example, the
tyrosine kinase inhibitor Imatnib (Gleevec), targets the Warburg effect by decreasing
glucose uptake through down-regulation of GLUT-1 transporters resulting in less lactate
production in K562 cells (Gottschalk et al., 2004).
Lactate dehydrogenase the enzyme responsible for the reversible interconversion
of pyruvate to lactate, has two isoforms important in tumors. Lactate dehydrogenase A
(LDHA) is responsible for catalyzing for forward reaction producing lactate, and lactate
dehydrogenase B (LDHB), that catalyzes the reverse reaction of lactate conversion to
pyruvate. The ratio of LDHA/LDHB is an indicator of the glycolytic index of the cancer
and is linked to the invasiveness of the cancer (Arora et al., 2015). Small molecule
inhibitors of NF-kB, have been shown to up-regulate LDH-B and down-regulate LDH-A
expression levels in the breast cancer cell lines (MCF7 and MDA-MB-231), reducing the
production of lactate, reversing the Warburg effect and reducing the metastatic potential
of the breast cancer cells, MCF7 and MDA-MB-231 (Arora et al., 2015).
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Thus, the Warburg effect is important in these cancer cell lines and utilizing this
increased glucose uptake and abnormal metabolism to serve as a physiological
therapeutic target for anticancer treatments of triple negative breast cancer (MCF-7 and
MDA-MB-231) and myelogenous leukemia (K562) is a promising future research area.
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1.4

Monocarboxylate Transporters

The monocarboxylate transporter (MCT) family includes 14 transporters, from which
only a few, shown in Table 1.1, have been described as proton-linked short-chain
monocarboxylic acid transporters (Draoui et al., 2014; Halestrap et al., 2003). They are
MCT1-MCT4 (Halestrap & Meredith, 2004). The schematic structure of MCT1 is shown
in Figure 1.6 and is represented by 12 alpha-helical transmembrane segments with amino
and carboxyl termini located on the cytoplasmic side of the cellular membrane (Poole,
Sansom & Halestrap, 1996). The transmembrane sequences are conserved among the
isoforms, while the carboxylic terminus varies the most (Philp et al., 2001). The
concentration gradient of protons and monocarboxylates such as pyruvate, lactate, and
ketone bodies dictates the direction in which that substrate will be transported (Halestrap
et al., 2012).
In addition to being present in the cell membrane, MCTs are also found inside the
cell in the mitochondrial membrane (Brooks, Dubouchaud, Brown, Sicurello & Butz,
1999). While MCT1 is expressed in low levels in most mammalian tissue, especially
heart tissue, and red skeletal muscles that oxidize lactate, the expression of other MCTs
varies greatly depending on the tissue (Poole et al., 1996; Doherty & Cleveland, 2013;
Nancolas, Sessions, & Halestrap, 2015). In skeletal muscles, MCT1 was identified as the
mitochondrial lactate-pyruvate transporter (Hashimoto, Hussien & Brooks, 2006). MCT2
was found to be expressed in mitochondria and peroxisomes of liver tissue, as well as
neurons, testes, the cytoplasm of prostate cancer cells, and colorectal tumors (Valença et
al., 2015; Lee, Lee, Kang & Park, 2012; Doherty et al., 2013; Halestrap & Price, 1999).
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Table 1.1: Biochemical and Physiological properties of MCT family

PROTEIN

PREDOMINANT

NAME

SUBSTRATES

MCT1

Lactate, pyruvate,
ketone bodies
Pyruvate, lactate,
ketone bodies
Lactate

MCT2
MCT3

MCT4

Lactate, pyruvate,
ketone bodies

MAMMALIAN
TISSUE
DISTRIBUTION
Ubiquitous
Kidney, brain
Retinal pigment
epithelium,
choroid plexus
Skeletal muscle,
chondrocytes,
leukocytes, testis,
lung, placenta,
heart
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Km value

L-lactate 3–6 mmol/L
Pyruvate 1–2.5 mmol/L
L-lactate ~0.7 mmol/L
Pyruvate ~0.08 mmol/L

L-lactate 25–30 mmol/L
Pyruvate 150 mmol/L

Figure 1.6. Schematic representation of an MCT1. The basic structure of an MCT
protein consists of 12 alpha-helical transmembrane segments. Both, carboxyl and amino
ends of the protein are located on the cytoplasmic side of the membrane. A large loop is
projecting inwardly between transmembrane domains 6 and 7. The sequences coding for
the segments embedded in the membrane are conserved among the MCT isoforms.
CD147 is a transmembrane chaperone glycoprotein associated with MCT1, and MCT4.
CD147 assists in folding and stability, and is required for the membrane expression of
MCT1 and MCT4.
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It was also observed that MCT2 possesses the highest affinity for lactate and
pyruvate when comparing to MCT1 and MCT4, hence, in rats, it is found to be expressed
in tissue responsible for gluconeogenesis such as liver and kidney, as well as cells using
lactate for oxidation, such as neurons (Ullah, Davies & Halestrap, 2006; Bröer,
Schneider, Bröer, Rahman, Hamprecht & Deitmer, 1998). Knockdown of MCT2 in
colorectal cancer tissue resulted in cell cycle arrest by disturbing the mitochondrial
function (Lee et al., 2012).
Mouse MCT3, which is structurally similar to human MCT3, is found in choroid
plexus epithelia and retinal pigment, while in chickens MCT3 is expressed in retinal
epithelium only (Philp et al., 2001). MCT4 is expressed mainly in highly glycolytic tissue
such as white skeletal muscle fibers, tumor cells, white blood cells, and astrocytes
(Halestrap & Wilson, 2012). The levels of MCT4 were observed to become especially
upregulated by hypoxia-inducible factor 1α (HIF-1α) under hypoxic conditions in bladder
cancer cells, cervical cancer, and glioblastomas (Ord, Streeter, Roberts, Cranston &
Harris, 2005; Ullah et al., 2006; Miranda-Gonçalves et al., 2013). Therefore, it can be
seen that MCT expression levels differ among various tissue, and are also affected by
hypoxic conditions. When not enough oxygen is supplied to the tissue, and the cells start
utilizing glycolysis for energy production, the expression of MCT1 and MCT4 for lactate
export, increases to prevent a pH drop inside the cell (Halestrap et al., 2012). The
mechanism of action first involves the binding of a proton to the transporter, then the
binding of a monocarboxylate, and after the transport across the membrane takes place,
the substrate and the proton are released (Halestrap et al., 1999). Due to the importance of
MCTs in monocarboxylate transport, their expression levels, particularly MCT1 and
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MCT4, are now being considered in cancer prognosis (Pinheiro et al., 2012). The levels
of both MCT1 and MCT4 have been noticeably upregulated in breast, cervical,
colorectal, and gastric cancers, along with some glioblastomas. Consequently these two
representatives of the MCT family have become important novel targets for cancer
therapy (Miranda-Gonçalves et al., 2013; Pinheiro et al., 2010).
The transmembrane glycoprotein, CD147, also known as basigin or extracellular
matrix metalloproteinase inducer (EMMPRIN), is a chaperone protein associated with
MCT1 and MCT4 (Granja, Marchiq, Floch, Moura, Baltazar & Pouysségur, 2014). Along
with facilitating MCT1 and MCT4 in folding and stability, CD147 is required for MCT1
and MCT 4 membrane expression (Kirk, Wilson, Heddle, Brown, Barclay & Halestrap,
2000). The levels of CD147 were upregulated collectively with MCT1 and MCT4 in lung
cancer cells, and renal cell carcinomas (Granja et al., 2014).
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1.5

Lactate and lactate shuttle
Lactate, once considered a waste product of glycolysis, has emerged as an

important metabolic precursor and a source of energy. After being imported inside the
mitochondria, lactate can be reoxidized into pyruvate. NADH generated during this
conversion is used in the electron transport chain, while the pyruvate is utilized by the
TCA cycle, once again generating reducing equivalents during the process (Hashimoto,
Hussien & Brooks, 2006). The lactate released after strenuous exercise in muscle is one
of the main gluconeogeneic precursors in hepatic tissue (Bergman, Horning, Casazza,
Wolfel, Butterfield & Brooks, 2000). MCT1 has a higher affinity for pyruvate than
lactate. However, since the concentration of lactate inside the cytosol is ten times higher
than that of a pyruvate, lactate is the main substrate that is being transported into the
mitochondrial intermembrane space (Brooks et al., 1999; Dubouchaud, Butterfield,
Wolfel, Bergman & Brooks, 2000). Although it has been proposed that lactate levels can
be used as a prediction of metastatic risk in some cancers, recent studies of human breast
cancer cells in vivo in mouse xenograft have shown that the level of glycolysis and
lactate production in a more metastatic tumor was in fact lower than in a less metastatic
(Xu et al., 2014).
Also worth mentioning is the fact that at physiological pH lactic acid, with pKa
value of approximately 3.8, exists in an unprotonated form, completely dissociated into
lactate and a hydrogen proton, hence “lactic acid” is not an appropriate term to use when
describing fermentation reaction products in the cell (Robergs, 2004).
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1.6

MCT inhibitors
When the mechanism of lactate transport in cancer cells became clear, the next

step was naturally to try to determine how the cells would behave when deprived of the
lactate export mechanism. One of the biochemical molecules used for the purpose of
blocking MCT transporters is α-cyano-4-hydroxycinnamate (CHC). CHC is a substituted
aromatic monocarboxylate and a potent, reversible competitive inhibitor of MCT
transporters. Although CHC proved to be an effective MCT1 inhibitor, it also decreases
mitochondrial pyruvate transport by inhibiting the mitochondrial pyruvate carrier (MPC),
a protein unrelated to the monocarboxylate transporters (McCommis & Fink, 2015),
therefore leading to hindrance of pyruvate oxidation (Halestrap & Denton, 1975).
Another potent MCT inhibitor, AR-C155858, was discovered by AstraZeneca
(Ovens et al., 2010). AR-C155858 was first created to function as an immunosuppressant
to block the proliferation of T-lymphocytes, but eventually the drug found its application
in cancer treatment (Nancolas, Sessions, & Halestrap, 2015). AR-C155858 binds to
MCT1 and MCT4 intracellularly and inhibits the transporter, as shown in Figure 1.7, but
has no effect on MCT4 function up to a concentration as high as 10 M (Ovens et al.,
2010; Nancolas et al., 2015). When the effects of AR-C155858 were studied in Xenopus
oocytes, the drug inhibited MCT1 and MCT2 with similar potency, yet was inactive
against MCT4 expressing oocytes (Ovens et al., 2010). Interestingly, the inhibition of
MCT2 was only observed when the transporter was associated with the basigin protein
(Nancolas et al., 2015). AZD3965 is a MCT1 inhibitor derived from AR-C155858, and is
now in Phase I clinical trials in patients with adult solid tumors, prostate cancers, gastric
cancers, and diffuse large B cell (Polański et al., 2014). The preclinical study performed
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on small cell lung cancer (SCLC) demonstrated that cell lines that expressed MCT1 but
not MCT4 were found to be more sensitive to AZD3965, which means the level of MCT4
expression has a potential to become a predictive biomarker for response to cancer
treatment (Polański et al., 2014). Another study performed on SCLC xenografts
concluded that a significantly greater therapeutic effect was achieved by a combination of
treatment with an AZD3965 and radiation than the use of either modality alone (Bola et
al., 2014). This particular study brought attention to the potential of using an MCT1
inhibitor in combination with already available radiotherapy treatment options in order to
increase the anti-tumor effect.
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Figure 1.7. Antitumor profile of the MCT1 inhibitor AR-C155858. A schematic
depiction of the effect of AR-C155858 on MCT1 and MCT4 expressing cancer cell lines.
In the generic cancer cell, blocking both lactate efflux pathways will cause cell death
(top, left). If only MCT1 is inhibited, then lactate can still leave the cell through MCT4
(top, right). In K562 cells that predominately express MCT1 (middle), lactate efflux will
occur only through MCT1 (middle, left), which will cease upon block of the MCT1
transporter (middle, right) and result in the demise of the cell. In MCF-7 cells the
predominately express MCT4, the MCT1 inhibitor, AR-C155858 will have no effect on
lactate efflux, and hence cell viability (figure is modified from Draoui et al., 2014).
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1.7

Lactate shuttle models
A few models of lactate shuttle in cancer tissues have been proposed (Doherty &

Cleveland, 2013). The main idea uniting these models is that different areas of the tumor
express different lactate transporters, depending on the amount of oxygen available.
MCT4 is used to export lactate out of the cell to be consumed by other cancer tissue,
which in turn import the lactate via MCT1. For instance, the metabolic symbiosis model,
shown in Figure 1.8, states that hypoxic areas of the tumor are the areas rich in MCT4
expression and they export lactate. While the oxidative areas of the cancer tissue import
lactate, using MCT1 and essentially utilize it in the oxidative phosphorylation pathway
(Sonveaux et al., 2008). Another proposed model named “The Reverse Warburg Effect”,
describes the production of lactate by neighboring stromal fibroblasts that can be further
oxidized by tumor cells, also depicted in Figure 1.8 (Pavlides et al., 2009).
If the metabolic symbiosis model is indeed an accurate representation of the
tumor metabolism, the downside of trying to explore this particular mechanism is in the
difficulty of studying such a microenvironment in vitro. If the hypoxic area of the tumor,
with overexpressed levels of MCT4, exports lactate in the extracellular space for
utilization by the less hypoxic/oxidative area with overexpressed MCT1, it would make
sense to set up in vitro study of cells in hypoxic vs. normal environments. By looking at
the levels of MCT1 and MCT4 in cancer cell lines grown in hypoxic and normoxic
environments, it could be possible to establish if the amount of oxygen in the
environment is enough to generate a significant difference in the levels of expression of
lactate transporters. Furthermore, if the levels are significantly different and hypoxic
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Figure 1.8. Schematic representation of two models of lactate shuttling in cancer
cells. A. The reverse Warburg Effect representing the production of lactate by stromal
fibroblasts which is further oxidized by tumor cells to produce ATP. B. In the metabolic
symbiosis model Warburg metabolism cancer cells, export lactate through MCT4, while
the oxidative areas import lactate using MCT1 and essentially utilize it in the oxidative
phosphorylation pathway (Figure modified from Doherty et al., 2013).
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cells express MCT4 while cells in the presence of adequate amount of oxygen express
relatively more MCT1, applying an MCT1 inhibitor to hypoxic cells will not result in the
same effect as when the drug is used on cells with a physiologically normal oxygen
supply.
It is important to take into consideration the effects that MCT1 inhibition may
demonstrate in vivo. Considering the metabolic symbiosis model, AR-C155858 would
only inhibit certain areas of the tumor, most likely the areas located near the blood supply
with enough oxygen, the areas that import lactate. The hypoxic areas will not be affected
by the drug and will continue creating an acidic extracellular environment by exporting
lactate and protons, eventually leading to an even greater reduction of pH in the
surrounding tissue.

1.8

Cell Cycle
The cell cycle progression is an important and complex process and is very well

regulated and managed by the relative balance of several types of cyclin and cyclindependent kinases (CDK) (Walker, & Assoian, 2005). The concentration of CDK
inhibitors also plays an important role in cell cycle progression (Wang, Wu, Lu, Ma, Sun,
& Tang, 2015). In most cancer cells an overexpression of cyclins and activation of CDKs
is involved in promotion of uncontrolled cell proliferation (Wongsirisin, Yodkeeree,
Pompimon, & Limtrakul, 2012). Finding a way to arrest the cell cycle of constantly
dividing cancer cell has long been a target of numerous cancer therapy drugs.
Interestingly, acidosis and hypoxia have been observed to affect cell cycle progression in
some cancers (Figure 1.9). For instance, the study performed on MDA-MB-231 cells
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Figure 1.9. Cytosolic acidification induces cell-cycle arrest in cancer cells. Inhibition
of the cell membrane monocarboxylate transporters rapidly acidifies the cytosol due to
the decrease in proton efflux. The lower the cell pH the more growth factors required to
enter the cell division cycle and when pHi decreases below pH 7.1, the cell is prevented
from entering the cell-cycle and is growth arrested in the G1 phase (Figure modified from
Parks et al., 2013).
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concluded that the response of the cells subjected to a prolonged exposure to a low pH is
a reduction in proliferation rate, and an induced G1 cell cycle arrest through the means of
autophagic vacuole formation (Wojtkowiak et al., 2012). Proton extrusion by cancer cells
to the surrounding environment (Figure 1.10) has several advantages including increased
growth rate, increases metastatic ability and decreased uptake of some chemotherapeutic
drugs (Webb et al., 2011). Recently, autophagy, which is a catabolic pathway resulting in
degradation by lysosomes and further recycling of proteins and organelles, has been
recognized as an important metabolic stress survival mechanism in cancer cells (Marino
et al., 2012). Microtubule associated proteins light chain 3 (LC3), which are precursors
for membrane bound proteins participating in formation of autophagophores, were found
to be upregulated after the MDA-MB-231 cells were subcutaneously injected into nu/nu
mice (Wojtkowiak et al., 2012). Furthermore, when the tumors were buffered with
sodium bicarbonate in vivo, the expression of LC3 was reduced, providing evidence that
the tumor acidosis was responsible for the formation of autophagic vacuoles
(Wojtkowiak et al., 2012). Moreover, human melanoma cells also reacted to acidic
culture conditions by accumulating LC3 autophagic vesicles (Marino et al., 2012).
Although autophagy is one of many mechanisms used by the cell to avoid apoptosis, the
important outcome associated with this survival mechanism is the arrest in G1 phase.

1.9

Purpose of the study and hypothesis
MCF7, MD-MBA-231, and K562 cells were the cells lines used in these

experiments. MCF7 is a luminal-like breast cell line, which is weakly invasive, and
expresses estrogen and progesterone receptors (Lacroix & Leclercq, 2004). This weakly

25

Figure 1.10. The inverted pH relationship of cancer cells. Normal cells are slightly
more acidic in the cytoplasm than in the external environment. In cancer cells, the high
metabolic activity and increased export of protons acidifies the external milieu and
increases the metastatic ability of the cancer. The acidified environment can protonate
neutral chemotherapeutic drugs, such as doxorubicin, preventing their diffusion into the
cell (Figure modified from Webb et al., 2011).
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metastatic cell line was reported to have low levels of CD147 and MCTs (Gallagher,
Castorino, Wang & Philp, 2007). MD-MBA-231 cells are estrogen and progesterone
receptor negative, mesenchymal-like breast cancer cells that have been demonstrated to
have high levels of MCT4 mRNA and protein expression when compared to cells derived
from normal mammary tissue. MD-MBA-231 cells are also highly invasive (Gallagher et
al., 2007; Lacroix et al., 2004). Silencing MCT4 in MDA-MB-231 cells using siRNA led
to a decrease in the cells’ migration ability (Gallagher et al., 2007). Although another
source claims MCT1 was not expressed in MDA-MB-231, PCR performed on this cell
line confirmed their presence (Hussien & Brooks, 2011). K-562 cells are an
erythroleukemia cell line derived from a patient with a chronic myeloid leukemia. K562
cells were chosen due to the reported absence of MCT4 expression (Lacroix et al., 2004).
In order to evaluate a cells’ reliance on the lactate shuttle mechanism, cell culture
media infused with different glucose concentrations was employed. A 5 mM glucose
concentration would represent the physiologically normal level of glucose in the human
body, while 25 mM glucose would represent a hyperglycemic state. Varying glucose
concentrations in the media aids in the determination of how much cells depend on the
MCTs for lactate transport. The greater glucose concentration in the media would lead to
a higher level of glycolysis, essentially causing increased proton production and therefore
increasing the necessity for lactate and proton export out of the cell. The expected result
for the MCF7 cell line would be a higher expression of MCT4 in the cells grown in the
increased glucose environment of 25 mM compared to cells grown in 5 mM containing
glucose media. The viability of MCF7 cells should not be affected by the drug due to the
presence of an additional transporter, MCT4. It was previously observed that MCT4
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over-expression in SCLC hypoxic cells was able to induce AZD3965 resistance,
correspondingly, MCT4 in MCF7 cells will most likely succeed in clearing enough
lactate out of the cell to prevent acidification of cells incubated with AR-C155858
(Polański et al., 2014).
K562 cells that do not express the lactate transporter MCT4, would fail to export
protons in the presence of AR-C155858 due to glucose still being imported inside the
cell, and the export of the fermentation products, lactate and protons, being hindered
through blocking of MCT1. All of the generated protons will end up being trapped inside
the cell. When the expression of MCT4 is absent and the MCT1 is blocked by an ARC155858 the state of cell-cycle arrest and cellular quiescence would most likely result.
Furthermore, with the increase of glucose in the media, inability to export protons should
lead to even more drastic decline in proliferation. Knockdown of MCT4 in mice resulted
in increased sensitivity to MCT1 inhibitor AZD3965 (Polański et al., 2014).
If the increased glucose makes a significant difference in cell viability, this
finding can be further explored in other cell lines and the plasma glucose concentrations
can be taken into consideration with the therapeutic application of an MCT1 inhibitor.
Also, the design of a MCT4 inhibitor, and simultaneous application of both MCT1 and
MCT4 blockers will produce a much greater result than the block of only one lactate
transporter. This difference in the metabolism of cancer cells has been a target of
numerous studies. The idea of finding a solution that can be used as a successful attack
strategy that can be applied to a variety of cancers is quite attractive. To find a
therapeutic target shared by most tumors in the form of an abnormal physiology and
turning it against the cell would be a magic bullet for cancer treatment.
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CHAPTER TWO

METHODS
2.1

Cell Culture
MCF7 (GFP) and MDA-MB-231 (RFP) human breast cancer cell lines were

obtained from Cell Biolabs, INC (San Diego, CA). K562 cells (obtained from American
Type Culture Collection, Manassas, VA), were a kind gift of Dr. Eric Mendenhall
(University of Alabama in Huntsville).
All cell lines were cultured in Dulbecco's Modified Eagle Medium (DMEM),
containing no phenol red, no glucose and no pyruvate. DMEM was supplemented with
10% fetal calf serum, 100 Units/ml of penicillin and 100 μg/mL of streptomycin solution,
glutamine or GlutaMAX™, non-essential amino acids and the appropriate amount of
glucose to give either 0.2 mM, 5 mM or 25 mM final glucose concentrations. All cell
culture reagents were purchased from (Life Technologies™, Carlsbad, CA). Cells were
passaged every 3-5 days by trypsinization and grown at 37 °C in a humidified 5% CO2
incubator. K562 cells were cultured in a similar manor, except they were a suspension
culture and did not need to be trypsinized. Cells were grown in T-25 or T-75 flasks, either
in 5 ml or 25 ml of media respectively. Cells were passaged with a 1:3 to 1:5 split every
3-5 days. For experiments, cells were used directly from the T-25 flasks or plated on 24
well or 96 well plates. For an example of the cell lines see Figure 2.1.
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The MCT1 inhibitor AR-C155858 (obtained from Tocris Biosciences,
Minneapolis, MN) and dissolved as a stock solution of 1 mM in DMSO (ATCC,
Manassas, VA) and stored at -20°C. The AR-C155858 was made up at a working
concentration of 1 M which would expose the cells to a final DMSO concentration of
0.1% DMSO.
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MCF7 (GFP)

MDA-MB-231 (RFP)

K562

Figure 2.1. Images of the MCF7, MDA-MB-231 and K562 cells used in this study.
Fluorescent or confocal microscope of the three cell lines used in this study. MCF-7,
MDA-MB-231 and K562 cells.
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2.2

K562 Cell Counting and Viability Assay.
K562 cells were counted and assayed for viability using a Tali® cell counter (Life

technologies™, Carlsbad, CA). K562 cells were centrifuged down for 2 min at 1200xg,
and supernatant removed and discarded and cells were resuspended in the desired volume
of media. To count cells and perform cell viability analysis, 100 l of cells are removed
and placed in an Eppendorf tube, 1 L of Tali® Viability Dead Cell Green solution
(SYTOX® Blue dye) is added and the contents mixed and allowed to incubate for 2-5 min
at RT in a dark place. For the viability assay, 25 ul of cells were removed and gently
pipetted into a Tali® slide, and the slide was inserted into the Tali® cell counter for
analysis. SYTOX® Blue dye is impermeable to live cells, but readily enters dead cells
where it can bind to nucleic acids, which enhances the dye’s fluorescence by >500-fold
when bound to DNA. SYTOX® Blue dye has excitation and emission maximums at
445/470 nm respectively and fluorescence was detected utilizing the Tali® cell counter
green LED excitation at 458 ± 20 nm and emission was measured at 495 nM through a
long pass filter. The Tali® Viability Kit – Dead Cell Green was used to identify dead cells
in a population, which showed a green fluorescence. Following the fluorescence emission
the cells were counted as a percentage of the total number of cells in the population. Cell
number was routinely ≈ 4x105 cells/ml and cell viability was usually ≈ 95%. This
procedure was essentially performed according to the manufacturer instructions (Tali®
Viability Kit – Dead Cell Green, Catalog no. A10787).
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2.3

K562 and MCF7 (GFP) Cell Viability and Apoptosis Assay
K562 or MCF7 cells were cultured in various media containing different

concentrations of glucose and with or without MCT1 inhibitors, for 72 hr. Cells were
then isolated for counting, viability, apoptosis and cell cycle assays.
In normal live cells, phosphatidylserine (PS) is located on the cytoplasmic surface
of the cell membrane. However, in apoptotic cells, PS is translocated from the inner to
the outer leaflet of the plasma membrane, thus exposing PS to the external cellular
environment. Annexin V protein can then be used as a tool to detect PS due to its high
binding affinity. Propidium iodide (PI) is a cell-impermeant fluorogenic DNA-binding
dye used for identifying necrotic cells. PI is impermeant to live cells, but easily enters
dead cells and stains them with red fluorescence upon binding to nucleic acids, which
enhances its fluorescence 20- to 30-fold.
After a cell population was stained using Annexin V Alexa Fluor® 488 and
Propidium Iodide, apoptotic cells exhibited green fluorescence, dead cells showed red
and green fluorescence (observed as yellow), and live cells showed no fluorescence.
Propidium iodide has an excitation maximum at 535 nm and an emission maximum of
617 nm when bound to DNA. It can be measured using the Red channel LED: 530 ± 20
nm and emission measured using the 585 LP EM filter on the Tali® Cell Counter. Alexa
Fluor 488 which has an excitation maximum of 495 nm and an emission maximum of
519nm, can be excited on using the green LED at 458 ± 20 nm and emission measured
using the 525/50 EM filter.
The procedure included harvesting cells, centrifuging them at 600 x g for 2 min
and removing and discarding the supernatant. The cells were then resuspended in 1X
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Annexin binding buffer, so that there was at least 100 μL of cells at a concentration of
approximately 5 × 105 to 5 × 106 cells/mL. 5 μL of Annexin V Alexa Fluor® 488
antibody was added to each tube with the cell suspension, and gently mixed. The cells
were incubated in the cell Annexin V Alexa Fluor® 488 mixture at room temperature in
the dark for 20 minutes. The cells were centrifuged at 600 x g for 2 min, supernatant
discarded and the pellet resuspended in 100 μL of fresh Annexin binding buffer. 1 μL of
Tali® Propidium Iodide was added to each 100 μL sample, and gently mixed. The sample
was incubated at room temperature in the dark for 5 minutes. This procedure was
performed according to the Tali® Apoptosis Kit – Annexin V Alexa Fluor® 488 and
Propidium Iodide kit instructions (Catalog no. A10788). The various cell numbers and
populations (live, dead and apoptotic) were obtained and plotted in Prizm.

2.4

Cell Cycle Assay
Quantification of cellular DNA content is a commonly used method for

monitoring cell cycle progression. As cells progress through the cell cycle, the amount of
DNA ultimately doubles. This doubling can be tracked and used to determine the cell
cycle phase (G1, S, and G2/M). Cells in the G1 phase have one set of paired
chromosomes. During the S phase cellular DNA begins to double, so that the amount of
DNA is between one and two times the amount in G1. Cells in G2/M phase have double
the amount of DNA compared to cells in G1 and contain two sets of paired
chromosomes. Thus, the amount of DNA in cells directly reflects which cell cycle phase
the cells are in.
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The Tali® Cell Cycle assay contains a solution of propidium iodide, RNase A, and
Triton® X-100 to permeabilize and label the cells. In brief, an aliquot of cells sufficient
to give between 4x105 and 5x106 cells/mL was taken, and washed by centrifugation at
500 x g for 5 min, the supernatant was removed and discarded. The cells were then
resuspended in PBS, and centrifuged again at 500 × g for 5 minutes, the PBS was
removed and the cells were resuspended in 70% ice-cold ethanol. The cells were frozen
at -20°C overnight. The frozen samples were removed from the -20°C freezer, defrosted
and centrifuged at 1000 × g for 5 minutes at 4°C, the ethanol was discarded and the cell
pellet was resuspended in 1m L of PBS. Cells were centrifuged down one last time at 500
× g for 10 minutes at 4°C and resuspended in 200 µL of Tali® Cell Cycle Solution. The
final step was the incubation of the cells for 30 minutes in the dark. Following the
incubation, the cells suspension was vortexed and 25 L of that suspension was removed
and slowly pipetted into a Tali® cell slide, and inserted into a Tali® Cell Counter.
Propidium iodide, when bound to DNA has an excitation and emission maximum of
535/617 nm, respectively. The emission was measured using the Red channel LED of the
Tali® Cell Counter with an excitation of 530 ± 20 nm and a long pathway emission filter
of 585 nm. As it was mentioned earlier, the cells in G2/M phase have double the amount
of DNA compared to cells in G1 hence twice the fluorescence of cells in G1 phase. This
procedure was performed using manufacturer instructions (Tali® Cell Cycle Kit - Catalog
no. A10798).
The cell number/fluorescence data from the Tali® was analyzed with FCS Version
5 (De Novo, Glendale, CA) and Multicycle AV (Phoenix Flow Systems, Inc., San Diego,
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CA) using the mathematical fitting models of Kallioniemi et al., 1994. The proportion of
cells in the G1, S and G2 phases was determined and plotted.

2.5

RNA isolation and cDNA generation
An appropriate number of cells, usually 5 x 106-1 x 107 cells were taken from

suspension culture or trypsinized off a T-25 flask, pelleted by centrifugation at 1000 x g
for 5 min and the supernatant discarded. Cells were resuspended in 175 L cold lysis
buffer (50 mM Tris·Cl, pH 8.0, 140 mM NaCl, 1.5 mM MgCl2, 0.5% Nonidet P-40). The
suspension was centrifuged at room temperature for 2 min at 300 x g, and the supernatant
transferred to a new tube. The supernatant was then pipetted onto a QIAshredder column
and centrifuged at 15,000xg for 2 min. 500 L of 100% ethanol was added to the sample,
and mixed well. The sample was then applied to a Quiagen RNeasy column and
centrifuged at 8000 x g for 15 s, and the flow through discarded. The column was washed
with several buffers, centrifuged at 8000 x g for 15 s and then centrifuged at maximum
speed for 2 min to dry the column and remove all traces of ethanol. The purified total
cellular RNA was eluted from the RNA binding column with 50 l of RNase-free water
by centrifuging for 1 min at 8000 x g. The concentration of RNA was quantified using a
Nanodrop spectrophotometer. Essentially the protocol was similar to the Qiagen
RNeasy® kit instructions (catalog No. 74104).
To make cDNA about 1 g of total cellular RNA was thawed on ice, and mixed
with a genomic DNAase and incubated at 42 °C for 2 min. The reaction mixture was then
chilled on ice for 2 min, and 1 l of Quantiscript Reverse Transcriptase was added. The
volume was adjusted to 20 l and the cDNA synthesis reaction was allowed to progress
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at 42 °C for 30 min. The RT was then inactivated by heating at 95 °C for 2 min. The
cDNA was then quantified using the Nanodrop spectrophotometer and frozen at -20 °C
until use for real-time PCR analysis. The protocol is essentially the same as that followed
by the QuantiTect Reverse Transcription Kit (Qiagen Catalogue No. 205311).

2.6

Real-time qPCR analysis
Real-time PCR was performed using a 7500 Fast Real-time PCR system (Life

technologies™, Carlsbad, CA). Real-time PCR was set up in a 96-well plate in a reaction
volume of 25 l per well. First 17.5 L of a master mix, prepared with 2x Fast SYBR®
Green, an appropriate cDNA, and DNA free water was applied to each well. 7.5 L of an
appropriate oligo was added to each well at the last step, each from a stock of 100 M
(Catalog number 4385617). For each pair of oligos (Figure 2.2), primer melt curves were
obtained to validate them. Water controls were always performed in each 96 well plate
experiment. PCR amplification was achieved for 40 cycles (Figure 2.3), and data was
obtained and analyzed for the threshold crossing cycle (CT). A typical example of a realtime PCR experiment is shown in Figure 2.4. The PCR efficiency was determined for the
target genes MCT1 and MCT4 by qPCR analysis of serial dilutions of cDNA (Figure
2.5). The threshold crossing point values (CT) were linearly correlated with the
logarithmic value of the DNA amount. The slope of this line provided the PCR efficiency
number for the gene under the given parameters (primers used and PCR-protocol).
PCR efficiency is ideally 2.0 (for doubling of DNA at each cycle). PCRefficiency = 10 (-1/slope). Dilutions of 1, 3, 9, 27 and 81 were done in triplicate. PCR
efficiency of MCT1 was 2.12 (n=3). The PCR efficiency of MCT4 was 1.96 (n=3). The
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PCR efficiency was determined for the reference (housekeeping) gene by qPCR analysis
of serial dilutions of cDNA SDHA gene (Figure 2.6).
To determine the fold change of MCT1 and MCT4 expression over the reference gene
SDHA we used the quantification method and guidelines of Pfaffl, 2001. The efficiencies
of all three genes examined in this study were close to the ideal efficiency of two, and we
simplified our analysis and assigned Etarget a value of two (Figure 2.5 and Figure 2.6).
The threshold crossing RT-PCR cycle (Ct) for reference and target genes were obtained
from the R-PCR cycler software.

Fold change over SDHA= (Etarget)Ct(ref-target)

(2.1)

The reference gene SDHA showed constant expression over different glucose
concentrations, therefore no normalization was needed and a simplified equation could be
used (Equation 2.1).
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Oligos for PCR and qPCR
MCT1_F
MCT1_R

TATTGGAGTCATTGGAGGTCTT
CCAGAGTACAGAGGAACACA

MCT4_F
MCT4_R

CCGTCAGTGTCTTCTTCA
GCAGCCAAAGCGGTTCA

SDHA_F
SDHA_R

TCTGCACTCTGGGGAAGAAG
CAAGAATGAAGCAAGGGACA

Figure 2.2. Oligos used for qPCR analysis of cell lines. All MCT oligos were
purchased from Qiagen Inc. (Valencia, CA). SDHA oligos were synthesized by Eurofins
MWG Operon LLC (Huntsville, AL). All oligos were dissolved at 100M in TE buffer
or nuclease free water, aliquoted and stored at -20oC until needed.
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Figure 2.3. PCR protocol for real-time PCR in Fast 7500 Real Time cycler. The
reaction was held at 95 °C for 15 s, then annealed at 60 °C for 30 seconds. The extension
step was for 60 s at 72 °C. The amplification cycle was repeated 40 times.
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Figure 2.4. Typical example of a q-PCR analysis using MCF-7 cells. MCT4
expression (light green), MCT1 expression (red lines) and SDHA reference gene
expression (dark green). Experiment performed on 12082014.
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Figure 2.5. PCR Efficiency of Target genes MCT1 and MCT4. The PCR efficiency
was determined for the target genes MCT1 (■) and MCT4 (●) gene by qPCR analysis of
serial dilutions of cDNA. The threshold crossing point values (Ct) were linearly
correlated with the logarithmic value of the DNA amount. The slope of this line provided
the PCR efficiency for this gene under the given parameters (primers used and PCRprotocol). PCR eff. is ideally 2.0 (for doubling of DNA at each cycle). PCR-efficiency =
10 (-1/slope). Dilutions of 1, 3, 9, 27, 81 were done in triplicate. PCR efficiency of MCT1
was 2.12 (n=3). The PCR efficiency of MCT4 was 1.96 (n=3).
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Figure 2.6. PCR Efficiency of reference gene SDHA. The PCR efficiency was
determined for the reference (housekeeping) gene by qPCR analysis of serial dilutions of
cDNA. MCT4 (●) gene .The threshold crossing point values (Ct) were linearly correlated
with the logarithmic value of the DNA amount. The slope of this line gives the PCR
efficiency for this gene under the given parameters (primers used and PCR-protocol).
PCR eff. is ideally 2.0 (for doubling of DNA at each cycle). PCR-efficiency = 10 (-1/slope).
1, 3 ,9, 27, 81 dilutions done in triplicate. PCR efficiency was 1.81 (n=3)
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The threshold crossing point values (Ct) were linearly correlated with the logarithmic
value of the DNA amount. The slope of this line gives the PCR efficiency for this gene
under the given parameters (primers used and PCR-protocol). PCR efficiency is ideally
2.0 (for doubling of DNA at each cycle). PCR-efficiency = 10 (-1/slope). Dilutions of 1, 3, 9,
27 and 81 fold were done in triplicate. PCR efficiency was 1.81 (n=3). We also examined
of the stability of reference gene SDHA from cells grown in three different glucose
concentrations (Figure 2.7). The expression of SDHA, as measured by crossing the
threshold (CT) did not vary more than 1 cycle, between cells grown in glucose
concentrations ranging between 0.2 and 25 mM.

2.7

Statistical analysis and graph plotting.
All data were plotted and statistical analysis performed using Prizm 6.05 graph

suite of software (GraphPad Software, Inc., La Jolla, CA). All data is shown as mean ±
SEM, with the number of experiments, n, shown in parenthesis. Statistical analysis was
performed using Student’s two-tailed t-test for unpaired samples, assuming both sets of
data follow a normal distribution around a mean and have an equal variance. Once a t
value was determined, a P-value was assigned from Student’s t-distribution. If the
calculated P-value was below the threshold chosen for statistical significance (P < 0.05),
then the null hypothesis was not accepted (Ho, there is no relationship between the two
measured phenomena) in favor of the alternative hypothesis (Ha, the two measured
phenomena are different).
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Figure 2.7. Stability of reference Gene SDHA in different glucose concentrations. An
example of the stability of reference gene SDHA from cells grown in three different
glucose concentrations.
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CHAPTER THREE

RESULTS
3.1

Expression levels of Monocarboxylate transporters in MCF7, MDA-MB-231,

and K562 cell lines
The expression level of mRNA for monocarboxylate transporters, MCT1 and MCT4 was
measured in the weakly invasive, estrogen positive breast cancer cell line, MCF7, using
real-time PCR (RT-PCR), Figure 3.1. The mRNA was isolated from MCF7 cells grown
in culture for 1 week in the presence of 5 mM or 25 mM glucose. The media was
refreshed every day.
MCF7 cells grown in 5 mM glucose showed 0.022 ± 0.009 (n=5) fold less
expression then the reference gene, succinate dehydrogenase complex, subunit A
(SDHA). The values did not change significantly when MCF7 cells were grown in 25mM
glucose, 0.025 ± 0.010 (n=5, P = 0.810). MCT4 levels were 780 fold higher in MCF7
cells being 19.50 ± 3.56, n=5 fold higher than the reference SDHA expression, which did
not change upon increasing glucose concentration to 25 mM, 21.98 ± 1.86 (n=5, P =
0.553). MDA-MB-231 cells grown in 5 mM glucose showed 0.0840 ± 0.0458 (n=5) fold
less expression then the reference gene SDHA, Figure 3.2. The expression levels did not
change significantly when MDA-MB-231 cells were grown in 25 mM glucose, 0.0581 ±
0.0219 (n=5, P = 0.6231).
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Figure 3.1. MCF7 cells express about 800 times more MCT4 than MCT1 and
expression levels are not altered by glucose concentration. MCF7 cells grown in 5 mM
glucose showed 0.022 ± 0.009, n=5 fold less expression then the reference gene SDHA.
The expression did not significantly change when MCF7 cells were grown in 25 mM
glucose, 0.025 ± 0.010, n=5 (P = 0.810). MCT4 levels were 780 fold higher in MCF7 cells
being 19.50 ± 3.56, n=5 fold higher than the reference SDHA expression, which did not
change upon increasing glucose concentration to 25 mM, 21.98 ± 1.86, n=5 (P = 0.553).
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MCT4 levels were about 250 times higher in MDA-MB-231 cells being 20.64 ±
4.14, n=5 fold higher than the reference SDHA expression, which did not change upon
increasing glucose concentration to 25 mM, 23.10 ± 5.76 (n=5, P = 0.738).
The expression level of mRNA for the MCTs, MCT1 and MCT4 was measured in
the myelogenous leukemia line, K562, using real-time PCR, Figure 3.3. K562 cells grown
in 5 mM glucose showed 42.93 ± 13.98 (n = 5) fold more expression of MCT1 than the
reference gene SDHA. This increased to 108.3 ± 25.38, n=4, (P = 0.0482) fold over the
reference gene SDHA when the media glucose concentration was increased to 25 mM
glucose. MCT4 levels were not dependent on glucose concentration, and were 1.294 ±
0.9612 (n = 5) times higher than the reference gene SDHA in 5 mM glucose concentration
and 1.255 ± 0.4260, n=4, (P = 0.9746) higher then SDHA gene expression in 25 mM
glucose containing media.
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Figure 3.2. MDA-MB-231 cells express about 250 times more MCT4 than MCT1 and
expression levels are not altered by glucose concentration. MDA-MB-231 cells grown
in 5 mM glucose showed 0.0840 ± 0.0458, n=5 fold less expression then the reference gene
SDHA. This did not change when MDA-MB-231 cells were grown in 25 mM glucose,
0.0581 ± 0.0219, n=5 (P = 0.6231). MCT4 levels were about 250 times higher in MDAMB-231 cells being 20.64 ± 4.14, n=5 fold higher than the reference SDHA expression,
which did not change upon increasing glucose concentration to 25 mM, 23.10 ± 5.76, n=5
(P = 0.738).
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Figure 3.3. K562 cells express about 40 times more MCT1 than MCT4 in 5 mM
glucose media and expression levels of MCT1 are increased 3 fold in higher glucose
concentration. K562 cells grown in 5 mM glucose showed 42.93 ± 13.98 (n = 5) fold
more expression of MCT1 than the reference gene SDHA. This increased to 108.3 ±
25.38, n=4 (P = 0.0482) fold over the reference gene SDHA when the media glucose
concentration was increased to 25 mM glucose. MCT4 levels were not dependent on
glucose concentration, and were 1.294 ± 0.9612 (n = 5) times higher than the reference
gene SDHA in 5 mM glucose concentration and 1.255 ± 0.4260, n=4 (P = 0.9746) higher
then SDHA gene expression in 25 mM glucose containing media.
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3.2

The MCT1 inhibitor AR-C155858 does not alter the viability of MCF7 cells,

but has a small effect on cell number.
Inhibition of the MCT1 transporter with 1 M AR-C155858 did not produce a
change in cell viability (Figure 3.4). In 5 mM glucose media MCF7 cell viability was
96.67 ± 0.2108%, n=6, and 96.83 ± 0.1667, n=6, after 72 hr in culture in the presence of
1 M AR-C155858 the MCT1 inhibitor (P = 0.5490, ns). In the 25 mM glucose media
K562 cell viability was 96.83 ± 0.4014, n=6, and it did not change after 72 hr in the
presence of the MCT1 inhibitor 1 M AR-C155858, and was 95.33 ± 1.054, n=6 (P =
0.2131, ns). Hence, there is no effect of the inhibition of MCT1 on MCF7 cells.
The number of cells grown in the culture media containing 5 mM glucose
increased from 99.99 ± 2.438%, n=6, to 117.1 ± 6.640% (n=6), Figure 3.5. An increase of
17.14 ± 7.073% (P = 0.0359) was observed. When the media glucose concentration was
increased to 25 mM, the effect of the MCT1 inhibitor 1 M AR-C155858 decreased cell
growth from 100.0 ± 2.175 % (n=6) in the DMSO control to 86.13 ± 4.947% (n=6). That
was a difference of 13.87 ± 5.404% (P = 0.0280). There is no effect of MCT1 inhibition
on MCF7 cell viability, however a small decrease in cell number after 3 days in culture
was noticed.

3.3

MCF7 cells are most frequently found in the G1 phase of the cell cycle.
Cell cycle phase was determined by propidium iodide fluorescence on fixed

MCF7 cells. Cell-cycle analysis was only performed in 25 mM glucose containing media,
as it was expected to show the greatest difference (Figure 3.6). In a typical example, the
amount of cells in the G1 phase of the cell cycle was 79.13%, the amount of cells in the
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G2 phase was 8.6% and the S phase was 12.27% (Figure 3.6). When MCF7 cells were
incubated for 72 hr in a culture with the addition of 1 M of the MCT1 inhibitor ARC155858, the distribution did not change significantly, with the majority of the cells in
the G1 phase of the cell cycle, 69.11%, versus 17.92% in G2 phase and 12.97% in S
phase (Figure 3.7).
The effect of the MCT1 inhibitor AR-C-155858 on the cell cycle was studied in
six independent experiments and the mean values of the control and 1 M AR-C155858
plotted and compared (Figure 3.8). The percentage of cells in G1 phase was high, being
about 76.97 ± 1.584%, n=6, in the control cells, which decreased to 65.18 ± 1.399%, n=6,
in the cells grown in the presence of 1 M AR-C155858. This was a decrease of 11.79 ±
2.114% (P = 0.0002) of the total cell population. There was no difference in the S phase
in cells grown with and without the inhibitor, 13.59 ± 2.085%, n=6, versus 19.42 ±
2.319%, n=6, respectively (P = 0.0914, ns). MCF7 cells grown in the presence of 1 M
AR-C155858 also showed no change in the percentage of cells in the G2 phase, 9.440 ±
1.345%, n=6, in control versus 15.40 ± 2.618%, n=6, in cells grown with the MCT1
inhibitor (P = 0.0702, ns). Hence, MCT1 inhibition in MCF7 cells does not cause G1
cell-cycle arrest, as there is no increase of the cell number found in G1, in fact there is a
small significant decrease, with no significant increase in either S1 or G2 peaks, which
was considered an experimental error.
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Figure 3.4. The MCT1 inhibitor AR-C155858 does not alter the viability of MCF7
cells. In 5 mM glucose media MCF7 cell viability was 96.67 ± 0.2108%, n=6, after 72 hr
in culture. There was no change in viability, 96.83 ± 0.1667, n=6, after 72 hr in culture in
the presence of 1 M AR-C155858 inhibitor (P = 0.5490, ns). In the 25 mM glucose
media K562 cell viability was 96.83 ± 0.4014, n=6, and it did not change after 72 hr in
the presence of the MCT1 inhibitor 1 M AR-C155858, and was 95.33 ± 1.054, n=6 (P =
0.2131, ns)
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Figure 3.5. The MCT1 inhibitor AR-C155858 causes a small decrease in MCF7 cell
number when grown in the presence of 25 mM glucose solution. The number of cells
grown in 5 mM glucose containing media in culture increased from 99.99 ± 2.438%, n=6,
to 117.1 ± 6.640%, n=6. That is an increase of 17.14 ± 7.073% (P = 0.0359). When the
media glucose concentration was increased to 25 mM, the effect of the MCT1 inhibitor 1
M AR-C155858 was a decrease in cell growth from 100.0 ± 2.175 %, n=6, in the
control growth to 86.13 ± 4.947%, n=6. That is a decrease of 13.87 ± 5.404% (P =
0.0280).
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Figure 3.6. MCF7 cells grown in 25 mM glucose media are most frequently found in
the G1 phase of the cell cycle. Cell cycle phase was determined by propidium iodide
fluorescence on fixed MCF7 cells. Cell number was plotted against fluorescence (a.u.)
for MCF7 cells incubated for 72 hr in a culture media supplemented with 25mM glucose.
The amount of cells in the G1 phase of the cell cycle was 79.13%, the amount of cells in
the G2 phase was 8.6% and the S phase was 12.27%.
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Figure 3.7. The MCT1 inhibitor AR-C155858 did not cause a shift into the S or G2
phase of the cell cycle in MCF7 cells grown in 25 mM glucose media. Cell cycle phase
was determined by propidium iodide fluorescence on fixed MCF-7 cells. Cell number is
plotted against fluorescence (a.u.) for MCF7 cells grown for 72 hr in culture
supplemented with 25mM glucose with the addition of 1 M of the MCT1 inhibitor ARC155858. The amount of cells in the G1 phase of the cell cycle was 69.11%, the amount
of cells in the G2 phase was 17.92% and the S phase was 12.97%.
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Figure 3.8. The MCT1 inhibitor AR-C155858 does not redistribute cell populations
between S and G2 cell cycle phases in MCF7 cells grown in 25 mM glucose. Cell
cycle phase was determined by propidium iodide fluorescence on fixed MCF7 cells. The
percentage of cells in G1 phase was high, being about 76.97 ± 1.584%, n=6, in the
control cells, which decreased to 65.18 ± 1.399%, n=6, in the cells grown in the presence
of 1 M AR-C155858. This was a decrease of 11.79 ± 2.114% (P = 0.0002) of the total
cell population. There was no difference in the S phase of cells grown with and without 1
M AR-C155858, 13.59 ± 2.085%, n=6, versus 19.42 ± 2.319%, n=6, respectively (P =
0.0914, ns). MCF7 cells in grown in the presence 1 M AR-C155858 also showed no
change in the percentage of cells in the G2 phase, 9.440 ± 1.345%, n=6, in control versus
15.40 ± 2.618%, n=6, in cells grown with the MCT1 inhibitor (P = 0.0702, ns).
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3.4

The MCT1 inhibitor AR-C155858 showed a small increase in K562 cell

viability.
In 5 mM glucose media, cell viability was 86.67 ± 0.6667%, n=6, after 72 hr
incubation period (Figure 3.9). Surprisingly, there was a small increase in viability to
88.67 ± 0.4944%, n=6, after 72 hr in incubation with 1 M AR-C155858, an increase of
2.000 ± 0.8300% (P = 0.0367). In the 25 mM glucose media K562 cell viability was
78.00 ± 0.6325%, n=6, and increased to 87.67 ± 0.4216%, n=6 in the population of cells
cultured with the MCT1 inhibitor, a difference of 9.667 ± 0.7601% (P = 0.0001). The
percentage of cells in apoptosis was also measured by fluorescent Annexin V protein
binding to PS on the surface of plasma membrane, Figure 3.10. K562 cells grown in 5
mM glucose showed an apoptotic proportion of 6.333 ± 0.4944%, n=6, after 72 hr in
culture. Addition of 1 M AR-C155858 caused no change, with a mean apoptotic
proportion of 7.500 ± 0.3416%, n=6 (P = 0.0809). In the 25 mM glucose media the
apoptotic proportion was 11.67 ± 0.9189%, n=6, and remained unchanged with 72 hr
incubation with 1 M AR-C155858 at 9.833 ± 0.6009, n=6 (P = 0.1259).

3.5

The MCT1 inhibitor AR-C155858 decreased K652 cell number by a

mechanism that was enhanced by glucose.
The number of cells grown in culture media supplemented with 5 mM glucose
decreased from 100.0 ± 3.465%, n=6, to 77.18 ± 3.877%, n=6, a change of 22.82 ±
5.200 % (P = 0.0014). When the glucose concentration was increased to 25 mM the
effect of the MCT1 inhibitor 1 M AR-C155858 decreased cell growth even more from
99.98 ± 2.267 %, n=6, in the control to 57.80 ± 2.288%, n=6.
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Figure 3.9. The MCT1 inhibitor AR-C155858 shows a small increase in K562 cell
viability. In 5 mM glucose media, cell viability was 86.67 ± 0.6667%, n=6, after 72 hr in
culture. Surprisingly, there was a small increase in viability to 88.67 ± 0.4944%, n=6,
after 72 hr incubation in the presence of 1 M AR-C155858. An increase of 2.000 ±
0.8300% (P = 0.0367) was observed. In the 25 mM glucose solution K562 cell viability
was 78.00 ± 0.6325%, n=6, and increases to 87.67 ± 0.4216%, n=6 in the population of
cells cultured with the MCT1 inhibitor 1 M AR-C155858, a difference of 9.667 ±
0.7601% (P = 0.0001).
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Figure 3.10. The MCT1 inhibitor AR-C155858 does not alter the percentage of
apoptotic K562 cells. K562 cells grown in 5 mM glucose showed an apoptotic
proportion of 6.333 ± 0.4944%, n=6, after 72 hr in culture. Addition of 1 M ARC155858 caused essentially no change, with a mean apoptotic proportion of 7.500 ±
0.3416%, n=6 (P = 0.0809). In the 25 mM glucose media the resting apoptotic proportion
was 11.67 ± 0.9189%, n=6, which again remained unchanged after 72 hr in the presence
of 1 M AR-C155858 at 9.833 ± 0.6009, n=6 (P = 0.1259).
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That is a decrease of 42.18 ± 3.221% (P = 0.0001). When comparing the effect of
increasing the glucose to 25 mM in the presence of AR-C155858, an additional 19.37 ±
4.501% (P = 0.0016) decrease in cell number was observed.

3.6

The MCT1 inhibitor AR-C155858 caused G1 cell cycle arrest in K562 cells.
Cell cycle phase was determined by propidium iodide fluorescence on fixed

K562 cells. Cell-cycle analysis was only performed in 25mM glucose containing media,
as it showed the greatest change in cell number (Figure 3.11), and hence should
demonstrate the biggest change in the cell-cycle phase difference. In a typical example,
the amount of cells in the G1 phase of the cell cycle was 28.63%, the amount of cells in
the G2 phase was 39.79% and the S phase was 31.59% (Figure 3.12). With the addition
of 1 M of the MCT1 inhibitor AR-C155858, the amount of cells in the G1 phase of the
cell cycle increased to 43.11%, the amount of cells in the G2 phase decreased to 17.38%
while the percentage of K562 cells in the S phase remained unchanged at 39.51% (Figure
3.13).
The cell cycle effect of the MCT1 inhibitor AR-C-155858 was studied in six
independent experiments and the means of control and 1 M AR-C155858 plotted and
compared (Figure 3.14). The percentage of cells in G1 phase was 26.46 ± 2.602%, n=6 in
the control cells, which increased to 39.29 ± 1.292%, n=6, in the G1 phase of cells grown
in the presence of 1 M AR-C155858. This was an increase of 12.83 ± 2.905% (P =
0.0013) of the total cell population. There was no difference in the S phase of cells grown
with and without 1 M AR-C155858, 36.56 ± 1.951%, n=6, versus 36.51 ± 3.753 %,
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n=6, respectively (P = 0.9908, ns). K562 cells in grown in the presence 1 M ARC155858 showed less cells in the G2 phase, decreasing from 36.98 ± 1.253%, n=6, in
control to 24.21 ± 3.386%, n=6, in cells grown with the MCT1 inhibitor, a decrease of
12.77 ± 3.611% (P = 0.0054) of the cell population. This suggests that MCT1 inhibition
in K562 cells caused a G1 cell-cycle arrest and can explain the 42.18 ± 3.221% decrease
in the cell number after 72 hr (Figure 3.11).
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Figure 3.11. The MCT1 inhibitor AR-C155858 decreases K652 cell number by a
mechanism that is affected by a glucose concentration. The number of cells grown in
5 mM glucose containing media in culture decreased from 100.0 ± 3.465%, n=6, to 77.18
± 3.877%, n=6. That is a decrease of 22.82 ± 5.200 % (P = 0.0014). When the media
glucose concentration was increased to 25 mM, the effect of the MCT1 inhibitor 1 M
AR-C155858 decreased the cell growth even more from 99.98 ± 2.267 %, n=6, in the
control to 57.80 ± 2.288%, n=6. Which is a decrease of 42.18 ± 3.221% (P = 0.0001).
When comparing the effect of increasing the glucose to 25 mM in the presence of ARC155858, an additional 19.37 ± 4.501% (P = 0.0016) decrease in cell number was
observed.

63

Figure 3.12. A typical example of cell cycle analysis of K562 cells grown in 25 mM
glucose media. Cell cycle phase was determined by propidium iodide fluorescence on
fixed K562 cells. Cell number is plotted against fluorescence (a.u.) for K562 cells grown
for 72 hr in culture supplemented with 25 mM glucose. The amount of cells in the G1
phase of the cell cycle was 28.63%, the amount of cells in the G2 phase was 39.79% and
the S phase was 31.59%.
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Figure 3.13. The MCT1 inhibitor AR-C155858 causes G1 cell cycle arrest in K562
cells grown in 25 mM glucose media. Cell cycle phase was determined by propidium
iodide fluorescence on fixed K562 cells. Cell number is plotted against fluorescence
(a.u.) for K562 cells grown for 72 hr in culture supplemented with 25mM glucose with
the addition of 1 M of the MCT1 inhibitor AR-C155858. The amount of cells in the G1
phase of the cell cycle was 43.11%, the amount of cells in the G2 phase was 17.38% and
the S phase was 39.51%.
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Figure 3.14. The MCT1 inhibitor AR-C155858 causes G1 cell cycle arrest in K562
cells grown in 25 mM glucose. Cell cycle phase was determined by propidium iodide
fluorescence on fixed K562 cells. The percentage of cells in G1 phase was 26.46 ± 2.602%,
n=6 in the control cells, which increased to 39.29 ± 1.292%, n=6, in the G1 phase of cells
grown in the presence of 1 M AR-C155858. This was an increase of 12.83 ± 2.905% (P
= 0.0013) of the total cell population. There was no difference in the S phase of cells grown
with or without 1 M AR-C155858, 36.56 ± 1.951%, n=6, versus 36.51 ± 3.753 %, n=6,
respectively (P = 0.9908, ns). K562 cells grown in the presence of 1 M AR-C155858
showed less cells in the G2 phase, decreasing from 36.98 ± 1.253%, n=6, in control to
24.21 ± 3.386%, n=6, in cells grown with the MCT1 inhibitor, a decrease of 12.77 ±
3.611% (P = 0.0054) of the cell population.
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CHAPTER FOUR

DISCUSSION AND CONCLUSIONS

4.1

Targeting the abnormal physiology of cancer
Targeting cancer by means of its abnormal physiology and metabolism has

become a popular strategy of cancer treatment. The increased glucose utilization and
lactate production creates a valid target for a small molecule in the form of the efflux of
lactate from the cell. Lactate is removed from the cell by co-transport with a proton, and
inhibition of these membrane localized monocarboxylate transporters (MCT) will cause
the intracellular buildup of protons, and cytoplasmic acidification. The working
hypothesis is that the cell cytoplasmic acidification will lead to an increase in cell death
(Figure 4.1).

4.2

Monocarboxylate transporter inhibition and cancer cell growth arrest
In this study the application of the MCT1 inhibitor AR-C155858 had no effect on

MCF7 cell number and viability in normal 5 mM glucose media. Increasing the glucose
to 25 mM resulted in a small decrease in cell number, and still no change in cell viability.
This absence of an effect of MCT1 inhibition can be explained by the large expression of
MCT4 in MCF7 cells, and the alternative export pathway for lactate and protons. In K562
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cells, the MCT1 inhibitor produced a 20% decrease in cell number after growth in 5 mM
glucose containing media. The change in inhibition of cell growth increased to about 40%
in K562 cells incubated in increased glucose containing media and exposed to the MCT1
inhibitor AR-C155858. Such a significant decrease in cell growth can be explained by the
majority of the lactate efflux being carried out by MCT1 in K562 cells, and a relatively
minor role of MCT4. Essentially, production of a glucose-stimulated intracellular
acidification takes place in high-MCT1 expressing but low MCT4 expressing cells. As a
result the acidification induced cell cycle arrest in the G1 phase, reducing cell division
and growth but not altering cell viability or number of apoptotic cells. Figure 4.2 shows a
model devised to describe the effect of MCT1 inhibition on MCF7 and K562 cells.

4.3

Future therapeutic applications of proton efflux inhibition in cancer cells.
Although this study concentrated on two particular proton-coupled lactate

transporters (MCT1 and MCT4), the range of transporters regulating proton efflux and
maintaining intracellular pH is quite wide. These include the Na+/H+ exchanger,
Na+/HCO3 co-transporter, the plasma membrane proton pump ATPase (V-ATPase),
carbonic anhydrases, anion exchangers and others (Damaghi et al., 2013, Parks et al.,
2013 and Figure 4.1). Each one of these proton efflux transporters can become a potential
drug target, alone or in combination. Besides considering the use of proton efflux
inhibitors alone, the application of these drugs inhibitors could be expanded to
combinations that target other pathways. For instance, modulating the metabolic state of
tumor cells has been successfully used as a sensitization strategy to radiotherapy in
glioblastoma cells by causing a G2/M cell cycle arrest (Shen et al., 2015).
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Figure 4.1. Multiple targets for inhibition of proton export and synergistic metabolic
inhibition. The multiple proton export pathways to target include the hypoxia-induced
carbonic anhydrase IX (CAIX), the monocarboxylate transporters, MCT1 and MCT4,
and the Na+/H+ exchanger 1 (NHE1). Proton pump inhibitors (PPI’s) will further reduce
cellular pH leading to cell-cycle arrest. Accumulation of cellular lactate will inhibit
glycolysis, leading to a decrease in cellular ATP levels. This metabolic stress could be
further enhanced with the application of metformin to inhibit mitochondrial ATP
production with the intent of conferring synergistic lethality. The convergence of
metabolic catastrophe, together with cellular acidification and cell-cycle arrest will likely
create unfavorable conditions for the cancer cell and decrease their viability (Figure
modified from Parks et al., 2013).
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Figure 4.2. The hypothetical mechanism of action of AR-C155858 MCT1 inhibitor
in MCF7 and K562 cell lines. The following model of MCT1 inhibition in MCF7 and
K562 cell lines was proposed. Due to the presence of an MCT4, the AR-C155858
inhibitor does not induce cell cycle arrest, neither does it have any effect on the cell
growth or cell number in MCF7 breast cancer cell. At the same time, the cell
proliferation, and the cell cycle of K562 were affected by the presence of AR-C155858
inhibitor. K562 cell lacking MCT4, and as a result of inability to export accumulating
protons out of the cell, the G1 cell cycle arrest was induced.
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Similarly, targeting pH regulators, such a MCT, has a potential to be widely used
in combination with other chemotherapeutic drugs in order to decrease the amount of
toxicity and side effects, while still achieving the goal of cancer elimination.

4.4

Proton efflux inhibition in combination with hyperglycemia: a novel

therapeutic approach for cancer treatment.
Recently, an immunofluorescence (IF) method for detection of MCT1 and MCT4
levels in circulating tumor cells has been explored emphasizing the importance of
evaluating MCT1 levels prior as well as after the treatment with AZD3965 to assess the
responsiveness of cancer to the drug (Kershaw et al., 2015). Hence, MCT1 is becoming a
prognostic biomarker for disease progression, while MCT4 expression levels are taken
into consideration as a biomarker for resistance to AZD3965 treatment in cells that retain
the ability to export lactate during glycolysis due to the high amount of an MCT4
expression (Kershaw et al., 2015). Undoubtedly, both transporters appear to have great
potential in cancer treatment and its prognosis. Although MCT4 expression levels were
proposed to be considered as a biomarker for resistance, a more proactive approach
would be to inhibit MCT4, along with MCT1 for a greater degree of elimination of a
lactate and a proton efflux. Considering the results of inhibition of MCT1 in K562 cells,
the same results could be achieved in almost any cancerous cell line, even the ones
expressing MCT4, if the MCT4 was also blocked from performing its function.
Furthermore, the increase of glucose in culture media confirmed the ability to induce
upregulation of glycolysis level, thereby inducting the state of acidosis through
intracellular accumulation of protons generated during the breakdown of glucose. Hence,
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the combination of MCT inhibitors with an induced hyperglycemic state is an efficient
strategy of cancer treatment. It is not uncommon for cancer cells to acquire drug
resistance in response to therapy. However, after a drastic metabolic alteration and a
major reliance on glycolysis it is highly unlikely that cancer cells will be able to reduce
their dependence on glycolysis, making the inhibition of pH regulators an even more
effective solution.

4.5

Conclusions

The current study extended the knowledge of the effects of an intracellular
acidification combined with an induced hyperglycemic environment in cancer cells. The
functional experiments performed during the study proved that an increased glucose level
in the media combined with an application of a pH regulator inhibitor were able to cause
a cell cycle arrest in cancer cells. Better understanding of the mechanism involved in cell
cycle arrest and inhibition of cell growth induced by intracellular acidification could help
in designing a more effective cancer treatments.
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